SouthState Corp’s Royalty Pharma RPRX Stock Holding History

SouthState Corp’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-101	Closed	-$3.56K	–	1435
2025 Q3	$3.56K	Buy	+101	New	+$3.66K	﹤0.01%	818

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SouthState Corp's RPRX Position: Q4 2025 in Review

SouthState Corp sold out of Royalty Pharma (RPRX) in Q4 2025, closing a stake of 101 shares — an estimated $3.56K sold.

SouthState Corp first reported a position in RPRX in Q3 2025 and held it in 1 quarter. The position peaked at $3.56K in Q3 2025. 540 funds tracked by Wall St. Rank hold RPRX as of Q4 2025.

SouthState Corp reported no remaining Royalty Pharma position as of Q4 2025 after selling out during the quarter.
SouthState Corp sold 101 Royalty Pharma shares in Q4 2025, an estimated $3.56K.
SouthState Corp first reported a position in Royalty Pharma in Q3 2025 and held it in 1 quarter.
SouthState Corp's Royalty Pharma position peaked at $3.56K in Q3 2025.
540 funds tracked by Wall St. Rank held Royalty Pharma as of Q4 2025.

Based on SouthState Corp's 13F filing for Q4 2025, filed 11 Feb 2026.